SB-590885 is a triarylimidazole that selectively inhibits Raf kinase and is a particularly potent inhibitor of B-Raf. SB-590885 exhibits anticancer chemotherapeutic activity through its ability to stabilize the oncogenic B-Raf kinase domain in an active configuration, therefore inhibiting downstream MAPK activation. SB-590885 also limits tissue damage after cerebral ischemia, displaying neuroprotective benefit.
| Cas No. | 405554-55-4 |
|---|---|
| Purity | ≥97% |
| Formula | C27H27N5O2 |
| Formula Wt. | 453.54 |
| Chemical Name | (E)-5-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-4-(pyridin-4-yl)-1H-imidazol-5-yl)-2,3-dihydroinden-1-one oxime |
| IUPAC Name | N,N-dimethyl-2-[4-[(4Z)-4-(1-nitroso-2, 3-dihydroinden-5-ylidene)-5-(1H-pyridin-4-ylidene)-1H-imidazol-2-yl] phenoxy]ethanamine |
| Solubility | DMSO 5 mg/mL (11.02 mM) Water Insoluble Ethanol Insoluble |
| Appearance | Light yellow solid |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Ahnstedt H, Säveland H, Nilsson O, et al. Human cerebrovascular contractile receptors are upregulated via a B-Raf/MEK/ERK-sensitive signaling pathway. BMC Neurosci. 2011 Jan 11;12:5. PMID: 21223556.
King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006 Dec 1;66(23):11100-5. PMID: 17145850.
